ABOUT US
About Recro Pharma
The Recro Pharma team is composed of experienced Pharma professionals, with a track record of successful product development and commercialization. Recro Pharma’s founder and CEO, Gerri Henwood, was previously the CEO and founder of two other successful start-ups, taking both companies to public company status on the NASDAQ (Auxilium: AUXL, and IBAH, acquired by a NYSE healthcare company). 
January 2010:
DEX-TD Phase I Clinical
Study initiated.
December 2009:
William Ashton joins Board
of Directors.
September 2009:
DEX-SL Phase I Clinical Study initiated in the U.S.
